Teva Pharmaceutical Industries Limited announced the Dr. Hafrun Fridriksdottir, Executive Vice President, Global R&D, will be leaving the company. Teva has initiated a search to identify its next head of Global R&D. Dr. Fridriksdottir plans to remain in her role until June 20, 2022 to assist with a smooth transition.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.88 USD | +0.16% | -2.65% | +23.37% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.37% | 14.59B | |
+25.46% | 659B | |
+25.38% | 557B | |
-4.86% | 359B | |
+16.44% | 322B | |
+8.34% | 297B | |
+6.13% | 215B | |
+2.93% | 210B | |
-7.65% | 200B | |
-8.79% | 149B |
- Stock Market
- Equities
- TEVA Stock
- News Teva Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Limited Announces Leaving of Hafrun Fridriksdottir, Executive Vice President, Global R&D, Effective June 20, 2022